Literature DB >> 11565542

A novel, possibly functional, single nucleotide polymorphism in the coding region of the thrombin-activatable fibrinolysis inhibitor (TAFI) gene is also associated with TAFI levels.

G J Brouwers, H L Vos, F W Leebeek, S Bulk, M Schneider, M Boffa, M Koschinsky, N H van Tilburg, M E Nesheim, R M Bertina, E B Gómez Garcia.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11565542     DOI： 10.1182/blood.v98.6.1992

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  14 in total

1.  Plasma carboxypeptidase B downregulates inflammatory responses in autoimmune arthritis.

Authors:  Jason J Song; Inyong Hwang; Kyung H Cho; Michael A Garcia; Arthur J Kim; Tiffany H Wang; Tamsin M Lindstrom; Annette T Lee; Toshihiko Nishimura; Lei Zhao; John Morser; Michael Nesheim; Stuart B Goodman; David M Lee; S Louis Bridges; Peter K Gregersen; Lawrence L Leung; William H Robinson
Journal:  J Clin Invest       Date:  2011-08-01       Impact factor: 14.808

2.  Thrombin-Activatable Fibrinolysis Inhibitor Gene Polymorphism (TAFI1040C/T) in Women With Recurrent Spontaneous Abortion.

Authors:  Nabil ElDanasori; Nelly Abulata; Iman A Shaheen; Alaa M ElGendy; Waleed El-Khayat
Journal:  Clin Appl Thromb Hemost       Date:  2017-02-22       Impact factor: 2.389

3.  A genome-wide exploration suggests an oligogenic model of inheritance for the TAFI activity and its antigen levels.

Authors:  Maria Sabater-Lleal; Alfonso Buil; Juan Carlos Souto; Laura Alamsy; Montserrat Borrell; Mark Lathrop; John Blangero; Jordi Fontcuberta; José Manuel Soria
Journal:  Hum Genet       Date:  2008-06-18       Impact factor: 4.132

Review 4.  Carboxypeptidase U (TAFIa): a new drug target for fibrinolytic therapy?

Authors:  J L Willemse; E Heylen; M E Nesheim; D F Hendriks
Journal:  J Thromb Haemost       Date:  2009-08-28       Impact factor: 5.824

5.  Low thrombin activatable fibrinolysis inhibitor activity levels are associated with an increased risk of a first myocardial infarction in men.

Authors:  Mirjam E Meltzer; Carine J M Doggen; Philip G de Groot; Joost C M Meijers; Frits R Rosendaal; Ton Lisman
Journal:  Haematologica       Date:  2009-04-18       Impact factor: 9.941

6.  Update on the Serum Biomarkers and Genetic Factors Associated with Safety and Efficacy of rt-PA Treatment in Acute Stroke Patients.

Authors:  C Nafría; I Fernández-Cadenas; M Mendioroz; S Domingues-Montanari; M Hernández-Guillamón; J Fernández-Morales; A Del Río-Espínola; D Giralt; L Deu; P Delgado; A Rosell; J Montaner
Journal:  Stroke Res Treat       Date:  2011-06-09

7.  Genetic variation in thrombin-activatable fibrinolysis inhibitor is associated with the risk of diabetic nephropathy.

Authors:  C-W Xu; X-B Wu; X-L Ma; Y-S Wang; B-C Zhang; J-J Zhao; Z-J Wang; J Chen
Journal:  J Endocrinol Invest       Date:  2012-07       Impact factor: 5.467

8.  Thrombin-activatable fibrinolysis inhibitor Thr325Ile polymorphism and plasma level in breast cancer: A pilot study.

Authors:  Manal S Fawzy; Eman A Mohammed; Amal S Ahmed; Abeer Fakhr-Eldeen
Journal:  Meta Gene       Date:  2015-04-11

9.  Biochemical characterization of bovine plasma thrombin-activatable fibrinolysis inhibitor (TAFI).

Authors:  Zuzana Valnickova; Morten Thaysen-Andersen; Peter Højrup; Trine Christensen; Kristian W Sanggaard; Torsten Kristensen; Jan J Enghild
Journal:  BMC Biochem       Date:  2009-05-05       Impact factor: 4.059

10.  Relationship Between Polymorphism of Thrombin-Activatable Fibrinolysis Inhibitor Gene +1040C/T and a Cohort of Chinese Women With Recurrent Spontaneous Abortion.

Authors:  Ping Fang; Decheng Cai; Lijun Du; Fei Shen; Chengfang Zhang; Meijuan Li
Journal:  Clin Appl Thromb Hemost       Date:  2021 Jan-Dec       Impact factor: 2.389
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.